

Eduardo Castanon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11340087/publications.pdf>

Version: 2024-02-01

30
papers

1,825
citations

623734

14
h-index

642732

23
g-index

31
all docs

31
docs citations

31
times ranked

2849
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytokines in clinical cancer immunotherapy. <i>British Journal of Cancer</i> , 2019, 120, 6-15.	6.4	720
2	Intratumoural administration and tumour tissue targeting of cancer immunotherapies. <i>Nature Reviews Clinical Oncology</i> , 2021, 18, 558-576.	27.6	202
3	Paradigms on Immunotherapy Combinations with Chemotherapy. <i>Cancer Discovery</i> , 2021, 11, 1353-1367.	9.4	197
4	Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score). <i>European Journal of Cancer</i> , 2017, 84, 212-218.	2.8	132
5	Prediction of Serious Complications in Patients With Seemingly Stable Febrile Neutropenia: Validation of the Clinical Index of Stable Febrile Neutropenia in a Prospective Cohort of Patients From the FINITE Study. <i>Journal of Clinical Oncology</i> , 2015, 33, 465-471.	1.6	118
6	Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. <i>Drug Safety</i> , 2019, 42, 281-294.	3.2	69
7	Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: the EPIPHANY study. <i>European Respiratory Journal</i> , 2017, 49, 1600282.	6.7	52
8	Intratumoral nanoplexed poly I:C BO-112 in combination with systemic anti-PD-1 for patients with anti-PD-1 refractory tumors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	51
9	Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy. <i>Journal of Translational Medicine</i> , 2013, 11, 13.	4.4	38
10	The inhibitor of differentiation-1 (Id1) enables lung cancer liver colonization through activation of an EMT program in tumor cells and establishment of the pre-metastatic niche. <i>Cancer Letters</i> , 2017, 402, 43-51.	7.2	36
11	Novel strategies exploiting interleukin-12 in cancer immunotherapy. , 2022, 239, 108189.		35
12	cMET in NSCLC: Can We Cut off the Head of the Hydra? From the Pathway to the Resistance. <i>Cancers</i> , 2015, 7, 556-573.	3.7	33
13	Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis. <i>Journal of Translational Medicine</i> , 2015, 13, 257.	4.4	26
14	Evidence of pseudoprogression in patients treated with PD1/PDL1 antibodies across tumor types. <i>Cancer Medicine</i> , 2020, 9, 2643-2652.	2.8	21
15	Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. <i>Gastric Cancer</i> , 2017, 20, 465-474.	5.3	20
16	A nomogram for predicting complications in patients with solid tumours and seemingly stable febrile neutropenia. <i>British Journal of Cancer</i> , 2016, 114, 1191-1198.	6.4	14
17	Critical reappraisal of phase III trials with immune checkpoint inhibitors in non-proportional hazards settings. <i>European Journal of Cancer</i> , 2020, 136, 159-168.	2.8	13
18	Anti-PD1 Induced Pneumonitis: Capturing the Hidden Enemy. <i>Clinical Cancer Research</i> , 2016, 22, 5956-5958.	7.0	12

#	ARTICLE	IF	CITATIONS
19	Patterns of progression in patients treated for immuno-oncology antibodies combination. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 221-232.	4.2	12
20	Differential Tumor Expression of Inhibitor of Differentiation-1 in Prostate Cancer Patients With Extreme Clinical Phenotypes and Prognostic Implications. <i>Clinical Genitourinary Cancer</i> , 2014, 12, 87-93.	1.9	8
21	Does active smoking worsen Covid-19?. <i>European Journal of Internal Medicine</i> , 2020, 77, 129-131.	2.2	8
22	Endoscopic and pathological dissociation in severe colitis induced by immune-checkpoint inhibitors. <i>Oncolmmunology</i> , 2020, 9, 1760676.	4.6	4
23	Neoadjuvant therapy for locally advanced gastric cancer patients. A population pharmacodynamic modeling. <i>PLoS ONE</i> , 2019, 14, e0215970.	2.5	3
24	A nomogram for predicting serious complications in patients with solid tumors and apparently stable febrile neutropenia: Prospective data on 781 consecutive episodes from the FINITE study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 165-165.	1.6	1
25	International Symposium: Trailblazing in Cancer Immunotherapy, October 29-31, 2017, Pamplona, Spain. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1809-1813.	4.2	0
26	Safety and efficacy of maintenance therapy (MT) with a nonspecific cytochrome-P 17 inhibitor (CYP17i) after response/stabilization to docetaxel in metastatic castration-resistant prostate cancer (mCRPC) patients.. <i>Journal of Clinical Oncology</i> , 2012, 30, 145-145.	1.6	0
27	Preliminary results of preoperative FOLFOX chemotherapy for locally advanced colon cancer patients with therapeutic drug monitoring of 5-FU.. <i>Journal of Clinical Oncology</i> , 2014, 32, 579-579.	1.6	0
28	Oxaliplatin, irinotecan, and PK-adjusted 5-fluorouracil within a multidisciplinary approach in patients with locally advanced pancreatic cancer (LAPC): Preliminary results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 356-356.	1.6	0
29	Familial clustering of prostate cancer (Pca) cases in a nonselected south European population (sEp).. <i>Journal of Clinical Oncology</i> , 2014, 32, 233-233.	1.6	0
30	Development and validation of a Clinical Index of Severe Febrile Neutropenia: A prospective multicenter study.. <i>Journal of Clinical Oncology</i> , 2015, 33, 9617-9617.	1.6	0